Stockscreener 앱 받기
0.7985
4.46%
-0.0373
시간 외 거래:
.84
0.0415
+5.20%
Traws Pharma Inc 주식(TRAW)의 최신 뉴스
Bandwidth, Traws Pharma and other big stocks moving lower in Monday's pre-market session - MSN
Traws Pharma stock falls as UK regulator delays key flu study - MSN
TRAW Downgraded by Ladenburg Thalmann -- Rating Changed to Neutr - GuruFocus
Traws Delays Influenza Study After UK Regulatory Setback - MyChesCo
Traws Pharma Stock Falls As UK Regulator Delays Key Flu Study - Benzinga
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Micron, Nebius surge premarket; Traws Pharma tumbles By Investing.com - Investing.com Australia
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study - Yahoo Finance
Why is Traws Pharma stock tumbling today? By Investing.com - Investing.com Canada
Traws Pharma stock tumbles after UK regulator delays flu trial By Investing.com - Investing.com Canada
Traws Pharma gains after hantavirus drug development update amid cruise ship outbreak - MSN
Traws Pharma Defers Phase 2a Human Influenza Study After UK MHRA Review, Advances Alternative Antiviral Candidates 1 – Minichart - Minichart
Traws Pharma (TRAW) Delays Phase 2a Trial of Tivoxavir Marboxil - GuruFocus
Why Did TRAW Stock Slump 28% After Hours? - Asianet Newsable
Traws Pharma Defers Phase 2a Influenza Study Plans - TipRanks
Traws Pharma Defers Phase 2a Study of Tivoxavir Marboxil Following UK Regulatory Review - Quiver Quantitative
Traws Pharma Provides Regulatory Update on Influenza Program | Associated Press | syndication news - Enidnews.com
Regulator setback stalls Traws Pharma bird flu drug test in humans - Stock Titan
Traws Pharma (NASDAQ: TRAW) defers Phase 2a influenza study, advances backup antivirals with runway to Q1 2027 - Stock Titan
Traws Pharma (TRAW) Finds Support, Edges Higher With Modest GainContinuation Pattern Picks - newsline.com
Traws Pharma, Inc. (TRAW) forms 'hammer chart pattern': Time for bottom fishing? - MSN
Traws Pharma (TRAW) Edges Lower as Stock Consolidates Near Key SupportBPI Bear Correction - newsline.com
TRAWS PHARMA INC (TRAW) Stock Chart - ChartMill
Traws Pharma Q1 2026 Earnings: EPS Surprise Beats Estimates Despite No Revenue, Stock Declines 7.4%SaaS Earnings Trends - newsline.com
Traws Pharma Dips as Company Expands Outbreak Drug Play - Bez Kabli
Traws Pharma (TRAW) Holds Near Key Support Amid Modest UptickVolume Nodes - newsline.com
TRAW | Traws Pharma, Inc. Common Executive Compensation - Quiver Quantitative
Traws Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift StockEstimate Accuracy - The Legal Advocate
Traws Pharma (NASDAQ: TRAW) 2026 proxy seeks share plan and warrant approvals - Stock Titan
Newtown-based Traws Pharma advances experimental antiviral therapy - Pennsylvania Business Report -
TRAW Q1 2026 Earnings: Narrower-than-Expected Loss Surprises on Lower ExpensesEarnings Recovery Stocks - The Legal Advocate
Traws Pharma announces new antiviral program - BioWorld News
TRAW Advances Novel Anti-Viral Agent for Hantavirus and Ebola - GuruFocus
Traws Pharma Advances Broad-Spectrum Antiviral for Emerging Outbreaks - TipRanks
Traws Pharma Advances Novel Broad-Spectrum Antiviral Agent Targeting Hantavirus, Ebola, and Lassa with Innovative Dual-Strike Mechanism - Quiver Quantitative
Traws Pharma (NASDAQ: TRAW) advances broad antiviral for Hantavirus, Ebola - Stock Titan
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks - GlobeNewswire
Traws Pharma, Inc. Files Form 8-K with SEC – Company Details, Address, and Legal Opinion Included - Minichart
TRAW - Finviz
Traws Pharma Updates ATM Equity Offering Prospectus Supplements - TipRanks
Traws Pharma launches $3.13M ATM sales under $50M shelf with Citizens JMP - TradingView
Traws Pharma (NASDAQ: TRAW) outlines $3,128,399 baby shelf ATM capacity - Stock Titan
Traws Pharma (TRAW) Stock Forecast & Analyst Ratings - Moomoo
Traws Pharma Inc. (TRAW) Q1 2026 Earnings: Narrower Net Loss Beats Estimates as Clinical Pipeline AdvancesGuidance Revision Trend - The Legal Advocate
Traws Pharma Q1 2026 Earnings: Narrowed Loss Surpasses Expectations Amid Pre-Revenue StageEarnings Growth Forecast - The Legal Advocate
Traws Pharma Inc. (TRAW) Q1 2026 Earnings: Better-than-Expected Losses Highlight Cost Discipline Amid Pre-Revenue PhaseElite Trading Signals - Newser
Traws Pharma Q1 2026 Earnings: Narrower Than Expected Loss Despite No RevenueSaaS Earnings Trends - The Legal Advocate
Traws Extends Runway With Financing as Flu Trial Nears - MyChesCo
Traws Pharma Inc files for offering of up to $3.1 million in common stock - marketscreener.com
Traws Pharma Inc Files For Offering Of Up To $3.1 Million In Common Stock - TradingView
TRAW (NASDAQ: TRAW) expands ATM by $3.13M under Citizens JMP agreement - Stock Titan
TRAW Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00 - GuruFocus
2.60%
0.94%
자본화:
|
볼륨(24시간):